Wild-type blocking PCR followed by direct sequencing offers a highly sensitive method of detection for low frequency somatic mutations in a variety of sample types.
Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging resistance mutations during therapy, or when patients have few circulating tumor cells. Wild-type blocking PCR followed by sequencing analysis offers high sensitivity, flexibility, and simplicity as a methodology for detecting these low frequency mutations. By adding a custom designed locked nucleic acid oligonucleotide to a new or previously established conventional PCR based sequencing assay, sensitivities of approximately 1 mutant allele in a background of 1,000 WT alleles can be achieved (1:1,000). Sequencing artifacts associated with deamination events commonly found in formalin fixed paraffin embedded tissues can be partially remedied by the use of uracil DNA glycosylase during extraction steps. The optimized protocol here is specific for detecting MYD88 mutation, but can serve as a template to design any WTB-PCR assay. Advantages of the WTB-PCR assay over other commonly utilized assays for the detection of low frequency mutations including allele specific PCR and real-time quantitative PCR include fewer occurrences of false positives, greater flexibility and ease of implementation, and the ability to detect both known and unknown mutations.
Sanger sequencing has traditionally been the gold standard in testing for both known and unknown somatic mutations. One of the limitations of Sanger sequencing is its limit of detection (~ 10 – 20% mutant allele in a background of WT)1. This level of sensitivity is inappropriate for detecting low level somatic mutations that may be present in samples from premalignant tissues or patients with few circulating tumor cells, or when bone marrow (BM) is patchy. This also makes assessing residual disease after therapy or detecting emerging resistance mutations during therapy difficult by conventional sequencing alone2. By replacing conventional PCR with locked nucleic acid (LNA)-mediated wild-type blocking PCR (WTB-PCR) in Sanger sequencing, sensitivities of up to 0.1% mutant allele in a background of WT can be achieved2,3,4. In WTB-PCR, enrichment for mutant alleles is achieved via the addition of a short (~ 10 – 14 NT) blocking (LNA) oligonucleotide that binds preferentially to WT DNA thereby preventing amplification of WT DNA. The mutant enriched WTB-PCR product can then be sequenced. By blocking WT DNA rather than selecting for specific mutations WTB-PCR allows for enrichment of both known and unknown mutations present in minute cell fractions.
Multiple methods are currently used for detecting mutations in small cells fractions. This includes allele-specific PCR, amplification-refractory mutation system (ARMS), denaturing high performance liquid chromatography (DHPLC), beads, emulsions, amplification, and magnetics (BEAMing), electric field-induced release and measurement (EFIRM), high resolution melting point and others. However, most of these methods are limited by false-positives and the ability to only detect one mutation that the assay was designed for4. WTB-PCR, however, allows the user to visualize sequencing traces which enables the detection of multiple mutation types and can aid in ruling out false positives due to artifacts or deamination events. Next-generation sequencing (NGS) may offer a suitable alternative to conventional sequencing, however, substantially greater costs, complexity, and longer assay time render it an unnecessary option for many disease types with few distinct molecular markers or for monitoring patients on therapy for emerging resistance mutations. Furthermore, high false positive rates when detecting variants with mutant allele frequencies of less than 5% can pose a problem for amplicon-based NGS5,6.
Here we demonstrate the increase in sensitivity achieved by WTB-PCR in screening for mutations in the myeloid differentiation factor 88 gene as described by Albitar et al.3 MYD88 mutations are important diagnostic and prognostic factors in Waldenström's Macroglobulinemia (WM), IgM monoclonal gammopathy of unknown significance (IgM-MGUS), splenic marginal zone lymphoma (SMZL), and diffuse large B-cell lymphoma (DLBCL). MYD88 mutations are found in almost all cases of WM and approximately 50% of patients with Immunoglobulin M (IgM)-secreting MGUS. Contrastingly, MYD88 mutations are found in only 0-6% of patients with SMZL and are absent in multiple myeloma7,8. Because overlapping morphologic, immunophenotypic, cytogenetic, and clinical characteristics between WM and SMZL or IgM-multiple myeloma can often complicate differential diagnoses, the presence of a MYD88 mutation may serve as a useful identifying factor9. MYD88 mutations have also been associated with greater disease burden in patients with DLBCL and poor overall survival following therapy7,10. Additionally, because MYD88 mutations are more frequently found in activated B-cell-like (ABC) DLBCL than germinal center B-cell-like (GCB) DLBCL or primary mediastinal B-cell lymphoma (PMBL), MYD88 mutation status may serve as a surrogate marker for the ABC subtype11,12.
The detailed protocol provided here serves as a template from which new assays can be developed or most existing sequencing assays can be easily adapted to accurately detect low frequency mutations in various sample types. The approach can also be used for monitoring and detecting resistant mutations that may develop in tumors or even bacteria that may develop while patients are being treated with targeted therapy or antibiotics. Furthermore, it addresses and remedies many of the issues associated with mutation enrichment, particularly in formalin-fixed paraffin-embedded (FFPE) tissue.
Ethics Statement: All testing of human samples was performed after obtaining Institutional Review Board (IRB) approval.
1. DNA Extraction from FFPE Tissue, Peripheral Blood, and Bone Marrow Aspirate
2. Wild-Type Blocking PCR
3. Sequencing of WTB-PCR Product
4. Analysis of Sequencing Results
A conceptual overview of WTB-PCR during extension is presented in Figure 1. Because a single nucleotide mismatch in the blocker-DNA hybrid greatly decreases its melting temperature (ΔTm=20 – 30 °C), amplification of the WT allele is blocked while mutant template DNA is free to complete extension17. In this manner, mutant DNA is amplified exponentially while WT DNA is amplified linearly.
A demonstration of the mutant enrichment achieved by WTB-PCR is presented in Figure 2. Genomic DNA from patients with and without mutations were tested by both conventional and WTB-PCR and then sequenced to demonstrate the typical enrichment achievable by WTB-PCR and a lack of false positives in WT DNA. The working concentration of blocker used in WTB-PCR MMX should be determined by titration experiments and should achieve the desired level of mutant enrichment while not resulting in false positives or blocking amplification of WT DNA entirely. Sequencing analysis of WTB-PCR product demonstrates enrichment for the mutant allele and a limit of detection in excess of 0.5% mutant allele in a background of WT compared with 16% in conventional PCR3.
The effects of this increase in sensitivity in clinical testing may vary depending on the relative quantity of neoplastic cells in the samples tested. In a methods comparison study, the WTB-PCR assay described here has demonstrated that 64% of MYD88 mutations would be missed by conventional testing of patients with WM or MGUS3.
A characteristic drop-off in signal intensity (Figure 3) is often seen if too high a concentration of blocker is used or if post-PCR purification failed to remove blocker prior to bi-directional sequencing. The latter is demonstrated when magnetic bead purification is substituted for enzymatic purification. Though enzymatic purification is an attractive option when working with greater sample numbers, it is inappropriate for application with WTB-PCR as it fails to remove blocker from solution prior to sequencing.
An example of sequence artifacts frequently found in FFPE-derived DNA as a result of cytosine deamination (C:G>T:A) are presented in Figure 43,18,19,20. Though the actual causes of cytosine deamination are poorly understood, any PCR based assay that enriches for mutant alleles will detect these low frequency artifacts21,22. False positives due to deamination are best avoided by starting with high quality template material; in the many cases where this is not possible, treatment with uracil DNA glycosylase (UDG) during extraction can aid in limiting the frequency and intensity of deamination artifacts. UDG treatment of FFPE tissue during extraction (as part of the DNA FFPE kit) excises deaminated cytosine residues thereby preventing artificially induced C:G>T:A mutations. However, 5-methylcytosine residues that frequently occur at CpG dinucleotides are deaminated to thymine, which cannot be excised by UDG. The resulting sequencing artifacts are fairly recognizable and often appear as tandem mutations as seen in Figure 4. If samples have already been extracted, UDG treatment can be implemented in a secondary extraction with relatively low DNA loss.
Figure 1: Conceptual Overview of WTB-PCR. A single nucleotide mismatch in the Blocker-DNA hybrid decreases Tm by up to 30 °C. By designing the blocking oligonucleotide to have a Tm of 10 – 15 °C above the temperature during extension, amplification of WT DNA is blocked while allowing amplification of mutant DNA. Please click here to view a larger version of this figure.
Figure 2: Genomic DNA from patients with and without mutations were tested by both conventional and WTB-PCR and then sequenced to demonstrate the typical enrichment achievable by WTB-PCR. The final concentration of blocker used to achieve WTB-PCR was selected to achieve maximum mutant enrichment while not causing false positives in WT DNA or blocking amplification of WT DNA entirely. Please click here to view a larger version of this figure.
Figure 3: Characteristic drop-off in signal intensity seen when enzymatic PCR purification is used instead of magnetic beads. This is likely because enzymatic purification fails to remove blocker prior to bi-directional sequencing. Please click here to view a larger version of this figure.
Figure 4: C:G>T:A sequencing artifacts arise in FFPE tissue when cytosine or methylated cytosine are deaminated via formalin fixation to uracil or thymine, respectively. Uracil DNA glycosylase (UDG) can excise uracil prior to WTB-PCR helping to reduce sequencing artifacts. However, thymine resulting from deaminated 5-methylcytosine, which frequently occurs at CpG islands, cannot be excised by UDG. Decreasing the concentration of blocker used in WTB-PCR may help to reduce the occurrence of sequencing artifacts that are not remedied by UDG treatment. Please click here to view a larger version of this figure.
The WTB-PCR assay described here uses a generic set of primers with a blocking oligo designed to block amplification of WT DNA during extension (Figure 1). The WTB-PCR product is then sequenced for mutational analysis. The utility of WTB-PCR/Sanger lies in its simplicity, high-sensitivity, and high-throughput. Using the guidelines described here, most existing Sanger based assays can be simply modified via the addition of a blocking oligonucleotide to greatly increase sensitivity. In the example assay presented here the addition of a single blocking oligonucleotide to PCR increased the limit of detection from approximately 16% mutant allele in a background of WT for the conventional assay to >0.5% in the WTB-PCR assay3. The effect of which is a 64% reduction in false negatives seen in clinical testing3. Confirming the presence of mutations in MYD88 has significant diagnostic and prognostic implications; falsely reporting a case as negative may have serious consequences on overall therapy and patient management. Testing with WTB-PCR is therefore of great importance, particularly in patients with relatively low abnormal cellularity.
WTB-PCR techniques vary considerably and are sometimes referred to interchangeably with LNA, BNA, or PNA-mediated PCR clamping or PCR-clamp-probe assays2,4,23,24. Some variations utilizing WTB-PCR involve a qPCR assay which necessitates designing an additional fluorescent probe for each specific mutation. A significant challenge associated with this technique includes the need to develop competitively binding probes that accurately discriminate between WT and mutant alleles. Furthermore, because a mutation specific probe is required, the qPCR approach lacks the ability to detect unknown mutations. Another variation of WTB-PCR blocks WT amplification in an allele-specific manner. Instead of using mutation-specific primers however, a blocking probe specific for the WT allele inhibits complete primer binding. While this approach does not require a mutation-specific probe like qPCR, it fails to discriminate between mutations and polymerase induced errors can lead to increased false positives. Exponential amplification of those polymerase induced errors through PCR may obscure the detection of rare mutational events. Any approach that uses PCR amplification to enrich for mutations has its accuracy limited by the frequency of PCR errors25,26,27. A fundamental advantage of WTB-PCR/Sanger over many other high-sensitivity methodologies is that it prevents amplification of both WT template and mutant template whose mutations occur outside the gene region targeted by the blocking oligonucleotide. Therefore, PCR errors introduced by polymerases are effectively filtered out along with WT DNA. Contrary to AS-PCR or qPCR however, enrichment is retained for unknown mutations that occur within the region covered by the blocking oligo. In the case of MYD88, WTB-PCR allowed the detection of both L265P and R264* mutations3. Others have similarly reported the detection of multiple, low-frequency mutations with the use of WTB-PCR4,28. This makes WTB-PCR ideal for both research and clinical purposes.
Along with high sensitivity and inherent internal controls for eliminating false positives, WTB-PCR's flexibility for adapting an existing sequencing assay with very few additional steps with blocker design make it attractive option for many labs with established assays. The same set of PCR primers used in a conventional assay can typically be used in the WTB-PCR variation. Other protocol changes that are highly recommended for WTB-PCR-including UDG treatment of FFPE tissue and appropriate post-PCR purification methodologies-are equally transferrable. Blocker design, therefore is the critical element in implementing a WTB-PCR assay. Though the guidelines presented in this protocol represent the most relevant factors in that design, various blocking oligonucleotides should be tested to find one that blocks WT amplification efficiently without secondary effects to PCR. This includes adding or removing blocker bases to adjust Tm, shifting the position of the blocking oligo relative to the WT template, and changing the overall length of the oligo. Blocker titration experiments should also be employed to establish a balance between acceptable occurrences of sequencing artifacts and limit of detection.
Selecting an appropriate methodology for detecting mutations that are present in minute cell fractions depends greatly on the application and disease/mutation types. If mutant quantification is desired, qPCR or digital PCR may offer more viable solutions than WTB-PCR/Sanger. Though WTB-PCR is primarily a qualitative assay, it is possible to determine a rough estimate of the mutant allele frequency by testing a sample with conventional and WTB-PCR in parallel. Because the limit of detection for the conventional assay is ~ 10 – 20% mutant allele in a background of WT, it is appropriate to conclude that mutations detected by the WTB-PCR assay but not the conventional are present at a concentration less than the limit of detection for the conventional assay. Few assays offer the versatility, simplicity, and robustness of WTB-PCR. The low cost and short turnaround time makes it ideal for assessing residual disease after therapy or monitoring emerging resistance mutations during therapy. Additionally, the ability to detect previously undescribed mutations make WTB-PCR ideal for research purposes.
The authors have nothing to disclose.
The authors have no acknowledgements.
1.5 or 2 ml Safe-Lock microcentrifuge tubes | Eppendorf | 05-402-25 | |
100% alcohol | VWR | 89370-084 | Histology grade; 91.5% Ethanol, 5% Isopropyl alcohol, 4.5% Methyl alcohol |
3730XL sequencer | ABI | or equivalent | |
Agencourt AMPure XP | Beckman Coulter | A63881 | For magnetic bead PCR purification |
Aluminum sealing foils | GeneMate | T-2451-1 | For PCR and cold storage |
BigDye Terminator v3.1 Cycle sequencing kit | Life Technologies | 4337455 | For bi-directional sequencing. With 5X Sequencing Buffer |
Centrifuge 5804 Series | Eppendorf | A-2-DWP rotor (for PCR plate) | |
Cold plate for 96 well plates | Eppendorf | Z606634 | |
DNAse, RNAse-free, ultra-pure water | |||
dNTPs (100mM) | Invitrogen | 10297-117 | |
DynaMag-96 Side-Skirted Magnet | Thermo Fisher Scientific | 12027 | For use in PCR Purification. |
Ethanol Absolute | Sigma | E7023 | 200 proof, for molecular biology |
Exiqon website Oligo Tools | www.exiqon.com/oligo-tools | ||
FastStart Taq DNA polymerase (5 U/ul) | Roche | 12032937001 | With10X concentrated PCR reaction buffer, with 20 mM MgCl2 |
Gel electrophoresis apparatus | 2% agarose gel | ||
GeneRead DNA FFPE extraction Kit | Qiagen | 180134 | Contains uracil DNA glycosylase necessary for reducing sequencing artifacts |
Hi-Di Formamide | ABI | 4311320 | For sequencing. |
LNA oligonucleotide | Exiqon | 500100 | 5'-TCAGA+AG+C+G+A+C+T+G+A+T+CC/invdT/ (+N = LNA bases) |
M13-F Sequencing Primer | ABI | 5'-tgt aaa acg acg gcc agt | |
M13-R Sequencing Primer | ABI | 5'-cag gaa aca gct atg acc | |
Mastercycler Pro S Thermocycler | Eppendorf | E950030020 | |
Microcentrifuge Model 5430 | Eppendorf | FA-45-30-11 rotor (for 1.5/2 ml microcentrifuge tubes) | |
NanoDrop 2000 Spectrophotometer | Thermo Fisher Scientific | ||
PCR forward primer | IDT | 5'-tgt aaa acg acg gcc agt TGC CAG GGG TAC TTA GAT GG | |
PCR reverse primer | IDT | 5'-cag gaa aca gct atg acc GGT TGG TGT AGT CGC AGA CA | |
PCR plates | GeneMate | T-3107-1 | |
Pipettors | 20, 200, 1000 µl | ||
Plate septa, 96 well | ABI | 4315933 | |
QIAamp DNA Mini Kit | Qiagen | 51304 | For BM aspirate and peripheral blood |
SeqScape Sortware v3.0 | ABI | 4474978 | For sequencing analysis |
Slide basket | |||
Sodium Acetate (3M, pH 5.2) | Sigma | S7899 | |
Sterile filtered pipette tips | 20, 200, 1000 µl | ||
Thermomixer C | Eppendorf | 5382000023 | |
Vortex genie | Scientific Industries | SI-0236 | |
Wash reservoir | ~1000 ml | ||
Xylene | VWR | 89370-088 | Histology grade |